7.74
Sagimet Biosciences Inc stock is traded at $7.74, with a volume of 835.70K.
It is up +1.71% in the last 24 hours and up +14.50% over the past month.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$7.61
Open:
$7.59
24h Volume:
835.70K
Relative Volume:
0.49
Market Cap:
$477.96M
Revenue:
$2.00M
Net Income/Loss:
$-43.51M
P/E Ratio:
-5.7697
EPS:
-1.3415
Net Cash Flow:
$-39.73M
1W Performance:
-0.64%
1M Performance:
+14.50%
6M Performance:
+41.76%
1Y Performance:
-6.18%
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SGMT
Sagimet Biosciences Inc
|
7.74 | 477.34M | 2.00M | -43.51M | -39.73M | -1.3415 |
|
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Rodman & Renshaw | Buy |
| Feb-03-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2500 Growth Benchmark - marketscreener.com
Sagimet Biosciences Added to Russell Indexes - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Index - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Value Benchmark - marketscreener.com
Sagimet Biosciences Inc. Class A Actuals & Estimates (NASDAQ:SGMT) - TradingView
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Sagimet Biosciences (SGMT) Joins Russell 3000 and Russell 2000 I - GuruFocus
Sagimet Biosciences added to Russell 2000 and 3000 indexes - Investing.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Growth Benchmark - marketscreener.com
Sagimet lands in Russell indexes as acne drug trial looms - Stock Titan
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 3000E Growth Benchmark - marketscreener.com
Price to earnings forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Enterprise value to EBITDA forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Enterprise value to EBITDA forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Price to book forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Price to sales forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Enterprise value to revenue forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Price to sales forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Sagimet Biosciences Inc (SGMT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
0O2 Forecast — Price Target — Prediction for 2027 - TradingView
SGMT Forecast — Price Target — Prediction for 2027 - TradingView
Sagimet Biosciences (SGMT) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Sagimet Biosciences Inc (SGMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sagimet Biosciences Announces Participation in Upcoming - GlobeNewswire
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade - Eastern Progress
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Sagimet Biosciences (SGMT) Edges Higher as Biotech Sector Gains MomentumScalping Stock Signals - dars.gov.et
SGMT Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive ReactionDividend Growth Analysis - dars.gov.et
SGMT News | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged - TipRanks
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Sagimet Biosciences Inc (SGMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sagimet Biosciences Inc (SGMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sagimet Biosciences Inc (SGMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sagimet Biosciences Inc (SGMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SGMT SEC FilingsSagimet Biosciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sagimet Biosciences Inc (SGMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sagimet Biosciences Inc (SGMT) Institutional Confidence - TradingKey
Sagimet Biosciences (SGMT) director receives 39,567 stock options grant - Stock Titan
Sagimet Biosciences (SGMT) director receives stock option grant for 39,567 shares - Stock Titan
Director at Sagimet Biosciences (NASDAQ: SGMT) receives 39,567 stock options - Stock Titan
Sagimet Biosciences (SGMT) director receives 39,567 stock options at $6.48 - Stock Titan
Sagimet Biosciences (SGMT) grants director Kemble George 39,567 stock options - Stock Titan
Director Anne Phillips receives 39,567 Sagimet (SGMT) stock options at $6.48 strike - Stock Titan
Sagimet Biosciences Announces Board Changes and Director Elections - TipRanks
Tim Walbert resigns from Sagimet's board - TradingView
Sagimet Biosciences (SGMT) director resigns as shareholders elect Board, ratify KPMG - Stock Titan
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sagimet Biosciences Inc Stock (SGMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chauche Thierry | Chief Financial Officer |
Feb 10 '26 |
Sale |
5.36 |
1,312 |
7,033 |
15,688 |
| Martins Eduardo Bruno | Chief Medical Officer |
Feb 10 '26 |
Sale |
5.36 |
3,640 |
19,511 |
103,296 |
| Rozek Elizabeth | Chief Legal & Admin. Officer |
Feb 10 '26 |
Sale |
5.36 |
2,622 |
14,054 |
190,959 |
| Kemble George | Executive Chairman |
Nov 20 '25 |
Sale |
7.69 |
37,688 |
289,979 |
81,005 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):